Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study
Markus Joerger, Sjaak A Burgers, Paul Baas, Egbert F Smit, Tjeerd J Haitjema, Martin P L Bard, Valerie D Doodeman, Paul H M Smits, Andrew Vincent, Alwin D R Huitema, Jos H Beijnen & Jan H M Schellens
To the authors' knowledge, this is the first prospective study to date in patients with advanced NSCLC describing predictive germline polymorphisms not only for the clinical activity of PG chemotherapy (ERCC1, XPD10) but also for its toxicity (GSTP1, RECQ1, CDA). Nonplatinum-containing chemotherapy in carriers of the ERCC1 T allele or the XPD10 G allele should be studied prospectively.
|citation||Joerger M, Burgers S A, Baas P, Smit E F, Haitjema T J, Bard M P L, Doodeman V D, Smits P H M, Vincent A, Huitema A D R, Beijnen J H, Schellens J H M. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 2011; 118:2466-75.|
|type||journal paper/review (English)|
|date of publishing||28-09-2011|
|journal title||Cancer (118/9)|